Rodman & Renshaw has recently initiated CorMedix Inc (CRMD) stock to Buy rating, as announced on August 26, 2024, according to Finviz. Earlier, on August 10, 2023, RBC Capital Mkts had initiated the stock to Outperform, setting a price target of $6. Needham also initiated Buy rating with a price target of $31. Additionally, JMP Securities initiated Mkt Outperform rating on September 29, 2020, with a target price of $22. Truist analysts, in their report published on September 21, 2020, also initiated Buy rating and set a price target of $20 for CorMedix Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
CorMedix Inc (CRMD) Stock Trading Recap
On Monday, CorMedix Inc (CRMD) stock saw a modest uptick, ending the day at $11.2 which represents a slight increase of $0.19 or 1.73% from the prior close of $11.01. The stock opened at $11.01 and touched a low of $10.9 during the day, reaching a high of $11.22. The volume of shares traded was 0.79 million falling short of the average volume of 0.85 million.
Sponsored
CRMD Stock Performance and Moving Averages
In recent trading, CorMedix Inc (CRMD) stock price has shown some volatility, fluctuating 11.33% over the last five trades and 51.76% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 112.12%, and it has gained 131.88% in the previous three months. Currently, CRMD is trading at 21.01%, 54.46%, and 121.22% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, CRMD, a Healthcare sector stock, is trading 1.54% below its 52-week high but remains 335.80% above its 52-week low. The Average True Range (ATR) (14 days) of 0.45 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
CorMedix Inc’s Profitability and Valuation Ratios
CorMedix Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -7212.47% and a profit margin of -6589.10%, with a gross margin of 112.12%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, CorMedix Inc’s market capitalization stands at $646.91 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The forward P/E ratio, which uses projected earnings for the next financial year, is 280. Additionally, the Price-to-Sales Ratio is 798.66, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 13.4, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.56% of CorMedix Inc (CRMD)’s shares, while financial institutions hold 29.58%.
